Hepatic Cell News Volume 4.07 | Feb 28 2020

TOP STORY

Hepatic Stellate Cell Activation Promotes Alcohol-Induced Steatohepatitis through Igfbp3 and SerpinA12

Investigators disrupted neuropilin-1 and synectin as models to evaluate the role of hepatic stellate cell activation on the development of steatohepatitis in response to alcohol feeding in mice. [J Hepatol] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors

Culture‐activated rat hepatic stellate cells were exposed to 0‐100 ng/ml lipopolysaccharide or its active component diphosphoryl lipid A, and parameters of fibrosis and inflammatory cytokines/chemokines were determined by q‐RT‐PCR, western and immunohistochemical analyses. [Hepatology] Abstract

Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death

The authors investigated the impact of twelfth-position trideuteration on the hepatic metabolism of and response to nevirapine. [J Med Chem] Abstract

Cellulose Nanofibril Hydrogel Promotes Hepatic Differentiation of Human Liver Organoids

A cellulose nanofibril hydrogel was investigated with regard to its potential to serve as an alternative clinical grade scaffold to differentiate liver organoids. [Adv Healthc Mater] Abstract | Full Article

Stiffer Matrix Accelerates Migration of Hepatocellular Carcinoma Cells through Enhanced Aerobic Glycolysis Via the MAPK-YAP Signaling

Researchers demonstrated that stiffer extracellular matrix (ECM) promoted hepatocellular carcinoma (HCC) cell migration depending on their accelerated aerobic glycolysis. They also indicated that stiffer ECM-induced YAP activation played a major role in promoting aerobic glycolysis of HCC cells. [Cancers] Full Article

Up‐Regulation of MicroRNA‐30b/30d Cluster Represses Hepatocyte Apoptosis in Mice with Fulminant Hepatic Failure by Inhibiting CEACAM1

Cell cycle distribution and apoptosis of hepatocytes of mice were determined by flow cytometry, and the target relation between miR‐30b/30d and CEACAM1 was confirmed by bioinformatic method and dual luciferase reporter gene assay. [IUBMB Life] Abstract

Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma

Investigators found that NOTCH1 signaling was activated in sorafenib-resistant hepatocellular carcinoma cells and NOTCH1 activation conferred hepatoma cells sorafenib resistance through enhanced self-renewal and tumorigenecity. [Transl Oncol] Full Article

EpCAM Inhibits Differentiation of Human Liver Progenitor Cells into Hepatocytes In Vitro by Activating Notch1 Signaling

The authors found that the epithelial cell adhesion molecule (EpCAM), a progenitor cell marker, regulated the differentiation of liver progenitor cells into hepatocytes through Notch1 signaling pathway. [Biochem Biophys Res Commun] Abstract

Bioactivation of Diclofenac in Human Hepatocytes and the Proposed Human Hepatic Proteins Modified by Reactive Metabolites

To reveal putative bioactivation pathways of diclofenac, in vitro human liver materials such as microsomal fractions and hepatocytes were used to confirm metabolic activation of diclofenac by ³⁵S-cysteine trapping assay and covalent binding assay. [Xenobiotica] Abstract

FAM13A Represses AMPK Activity and Regulates Hepatic Glucose and Lipid Metabolism

Scientists demonstrated that rs2276936 in this locus has allelic-enhancer activity in massively parallel reporter assays and reporter assay. The DNA region containing rs2276936 regulates expression of endogenous FAM13A in HepG2 cells. [iScience] Abstract | Graphical Abstract | Full Article

Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Pancreatic Cell News.

Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma

The authors elaborate on the current understanding of the signaling pathways involved in the development and initiation of hepatocellular carcinoma and anticipate the potential targets for therapeutic drug development. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the hepatic cell research field.

NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase II Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo

NGM Biopharmaceuticals, Inc. announced positive preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort of an adaptive Phase II study evaluating the efficacy, safety and tolerability of 1 mg aldafermin in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis. [NGM Biopharmaceuticals, Inc.] Press Release

Albireo Recognizes Rare Disease Day and Supports Global Effort to “Reframe Rare” By Highlighting the Challenges of Cholestatic Liver Disorders

Albireo Pharma, Inc. announced its support for Rare Disease Day 2020 and reaffirms its commitment to patients and families living with biliary atresia, Alagille syndrome, progressive familial intrahepatic cholestasis and other rare cholestatic diseases. [Albireo Pharma, Inc.] Press Release

Federal Judge Rules Clinical Trial Sponsors Must Publish a Decade’s Worth of Missing Data

For years, government research agencies have misinterpreted a law that requires them to collect and post clinical trial data, a federal judge ruled this week, leaving behind a 10-year gap in data that now must be made publicly available. [STAT News] Editorial

Contract Offers Unprecedented Look at Google Deal to Obtain Patient Data from the University of California

It was the fall of 2015 when researchers from Google and the University of California, San Francisco, first sat down together to hash out a research collaboration in an area that has since exploded with activity: using artificial intelligence to make predictions in the hospital. [STAT News] Editorial

NEW Tumor Heterogeneity: From Single Cells to Clinical Impact
September 10-13, 2020
Philadelphia, Pennsylvania, United States

Visit our events page to see a complete list of events in the community.

NEW Senior Postdoctoral Research Assistant – Liver Research (University of Dundee)

Postdoctoral Researchers – Diabetes, Liver, and Renal Disease (University of Oxford)

Network Manager – Non-Alcoholic Liver Disease (Hans-Knöll-Institute)

Postdoctoral Fellow – Fatty Liver Dieases (University of Kansas Medical Center)

Postdoctoral Fellow – Diabetes and Fatty Liver Disease (NIH National Heart, Lung, and Blood Institute)

Postdoctoral Position – Culturing ‘Foie Gras’ (KU Leuven)

Team Leader – Cholangiocytes (Miromatrix Medical)

Program Leader – Propionic Acidemia Research (Moderna)

Postdoctoral Fellow – Metabolic Dysfunction (Lewis Katz School of Medicine)

Postdoctoral Researchers – MicroRNAs in NAFLD (Weill Cornell Medicine)

Postdoctoral Fellow – Translational Cancer Research (University of New Mexico Comprehensive Cancer Center)

Research Associate – Liver Damage (University of Colorado Denver)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hepatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.